| Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction M Martignoni, GMM Groothuis, R de Kanter Expert opinion on drug metabolism & toxicology 2 (6), 875-894, 2006 | 1597 | 2006 |
| Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies IAM De Graaf, P Olinga, MH De Jager, MT Merema, R De Kanter, ... Nature protocols 5 (9), 1540-1551, 2010 | 485 | 2010 |
| Comparison of five incubation systems for rat liver slices using functional and viability parameters P Olinga, K Groen, IH Hof, R De Kanter, HJ Koster, WR Leeman, ... Journal of pharmacological and toxicological methods 38 (2), 59-69, 1997 | 139 | 1997 |
| Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine M Martignoni, G Groothuis, R de Kanter Drug Metabolism and Disposition 34 (6), 1047-1054, 2006 | 125 | 2006 |
| An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics L Vignati, E Turlizzi, S Monaci, P Grossi, R De Kanter, M Monshouwer Toxicology 216 (2-3), 154-167, 2005 | 114 | 2005 |
| Drug-metabolizing activity of human and rat liver, lung, kidney and intestine slices R De Kanter, MH De Jager, AL Draaisma, JU Jurva, P Olinga, DKF Meijer, ... Xenobiotica 32 (5), 349-362, 2002 | 114 | 2002 |
| An in vivo and in vitro comparison of CYP induction in rat liver and intestine using slices and quantitative RT-PCR M Martignoni, R de Kanter, P Grossi, A Mahnke, G Saturno, ... Chemico-biological interactions 151 (1), 1-11, 2004 | 92 | 2004 |
| A new technique for preparing precision-cut slices from small intestine and colon for drug biotransformation studies R de Kanter, A Tuin, E van de Kerkhof, M Martignoni, AL Draaisma, ... Journal of pharmacological and toxicological methods 51 (1), 65-72, 2005 | 91 | 2005 |
| Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry—do they comply with FDA recommendations? NJ Hewitt, R de Kanter, E LeCluyse Chemico-biological interactions 168 (1), 51-65, 2007 | 82 | 2007 |
| Organ slices as an in vitro test system for drug metabolism in human liver, lung and kidney R De Kanter, P Olinga, MH De Jager, MT Merema, DKF Meijer, ... Toxicology in vitro 13 (4-5), 737-744, 1999 | 78 | 1999 |
| The use of physiology-based pharmacokinetic and pharmacodynamic modeling in the discovery of the dual orexin receptor antagonist ACT-541468 A Treiber, R de Kanter, C Roch, J Gatfield, C Boss, M von Raumer, ... Journal of Pharmacology and Experimental Therapeutics 362 (3), 489-503, 2017 | 75 | 2017 |
| Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C A Weiss, E Lorthiois, L Barys, KS Beyer, C Bomio-Confaglia, H Burks, ... Cancer discovery 12 (6), 1500-1517, 2022 | 74 | 2022 |
| Prediction of whole-body metabolic clearance of drugs through the combined use of slices from rat liver, lung, kidney, small intestine and colon R De Kanter, M Monshouwer, AL Draaisma, MH De Jager, IAM De Graaf, ... Xenobiotica 34 (3), 229-241, 2004 | 74 | 2004 |
| A rapid and simple method for cryopreservation of human liver slices R de Kanter, P Olinga, I Hof, M de Jager, WA Verwillegen, MJH Slooff, ... Xenobiotica 28 (3), 225-234, 1998 | 61 | 1998 |
| Empirical validation of a rat in vitro organ slice model as a tool for in vivo clearance prediction IAM de Graaf, R de Kanter, MH de Jager, R Camacho, E Langenkamp, ... Drug metabolism and disposition 34 (4), 591-599, 2006 | 60 | 2006 |
| Discovery of a potent, selective T-type calcium channel blocker as a drug candidate for the treatment of generalized epilepsies O Bezencon, B Heidmann, R Siegrist, S Stamm, S Richard, D Pozzi, ... Journal of Medicinal Chemistry 60 (23), 9769-9789, 2017 | 52 | 2017 |
| Macitentan does not interfere with hepatic bile salt transport A Treiber, P Äänismaa, R de Kanter, S Delahaye, M Treher, P Hess, ... Journal of Pharmacology and Experimental Therapeutics 350 (1), 130-143, 2014 | 48 | 2014 |
| Characterization of novel antimalarial compound ACT-451840: preclinical assessment of activity and dose–efficacy modeling A Le Bihan, R de Kanter, I Angulo-Barturen, C Binkert, C Boss, R Brun, ... PLoS medicine 13 (10), e1002138, 2016 | 46 | 2016 |
| Phase I and phase II metabolic activities are retained in liver slices from mouse, rat, dog, monkey and human after cryopreservation M Martignoni, M Monshouwer, R de Kanter, D Pezzetta, A Moscone, ... Toxicology in Vitro 18 (1), 121-128, 2004 | 46 | 2004 |
| Cryopreservation of rat and monkey liver slices R de Kanter, HJ Koster Alternatives to Laboratory Animals 23 (5), 653-665, 1995 | 43 | 1995 |
